Protein / target
Receptor tyrosine-protein kinase erbB-3
Protein at a glance
Biological role
Protein tyrosine kinase activator
Primary biology
EGFR/ERBB growth-factor signalling
Strongest disease association
Visceral neuropathy, familial, 1, autosomal recessive
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins.
View complete UniProt function annotationHide complete annotation
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated by CSPG5 (PubMed:15358134). Involved in the regulation of myeloid cell differentiation (PubMed:27416908)
Subcellular location
Domains and Gene Ontology detail (47)Hide
Domains & features
Gene Ontology
- Capical plasma membrane
- Cbasal plasma membrane
- Cbasolateral plasma membrane
- CERBB3:ERBB2 complex
- Cextracellular space
- Clateral plasma membrane
- Cplasma membrane
- Cpostsynaptic membrane
- Creceptor complex
- FATP binding
- FErbB-3 class receptor binding
- Fgrowth factor binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Receptor tyrosine kinase signalling
- ·ERBB3:ERBB2 complex
- ·ErbB-3 class receptor binding
- ·cell surface receptor protein tyrosine kinase signaling pathway
- ·ERBB2-ERBB3 signaling pathway
Cell proliferation & survival
- ·regulation of cell population proliferation
- ·PIP3 activates AKT signaling
- ·PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
Growth-factor signalling
- ·growth factor binding
- ·epidermal growth factor receptor signaling pathway
Cell migration
- ·ERBB2 Regulates Cell Motility
Oncogenic signalling
- ·Constitutive Signaling by Aberrant PI3K in Cancer
Apoptosis & cell death
- ·negative regulation of apoptotic process
- ·negative regulation of neuron apoptotic process
- ·neuron apoptotic process
View underlying pathways (15)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
3 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Receptor tyrosine-protein kinase erbB-3 binding agent
ErbB-2/ErbB-3 heterodimer inhibitor
Indicated for Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene ERBB3
Gene-level evidence surfaced through the gene ERBB3that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
17 compounds recorded · 3 approved · 14 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Strong
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (14)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (20)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- New publicationPatritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial.
- New publicationEfficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.
- New publicationPatritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
- New publicationHERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Related family literature
Papers about “ErbB Receptors” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.
via ErbB Receptors
via ErbB Receptors
via ErbB Receptors
via ErbB Receptors
via ErbB Receptors
via ErbB Receptors
via ErbB Receptors
Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.